Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUVOX vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Premenstrual dysphoric disorder (PMDD),Bulimia nervosa,Post-traumatic stress disorder (PTSD)
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Primarily hepatic via CYP1A2; minor pathways via CYP2D6; active metabolites minimal.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
The apparent volume of distribution is about 4.7 L/kg, indicating extensive extravascular distribution and tissue binding, which contributes to its long half-life.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral bioavailability is approximately 53% after a single dose, with no significant food effect. Bioavailability may be higher under steady-state conditions due to saturation of first-pass metabolism.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥20 m L/min). Avoid use in severe renal impairment (Cr Cl <20 m L/min) due to lack of data.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh Class A: no dose adjustment; Child-Pugh Class B: reduce dose by 50% (start 25 mg/day, titrate cautiously); Child-Pugh Class C: contraindicated.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Children (8-17 years): start 25 mg orally once daily at bedtime; increase by 25 mg increments every 4-7 days to target dose; for OCD: 25-200 mg/day; maximum 200 mg/day. Weight not routinely used; dosing based on age and response.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Start 25 mg orally once daily at bedtime; titrate slowly (increases of 25 mg every 1-2 weeks); usual maximum 200 mg/day due to increased sensitivity and risk of hyponatremia.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in young patients,Serotonin syndrome,Activation of mania/hypomania,Seizure risk,Abnormal bleeding,Angle-closure glaucoma,Hyponatremia,QT prolongation,Sexual dysfunction,Discontinuation syndrome
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Concomitant use with MAOIs,Concomitant use with triptans,Hypersensitivity to fluvoxamine or any excipient,Pregnancy (relative)
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Avoid grapefruit juice as it inhibits CYP1A2 and can increase fluvoxamine serum concentrations, leading to toxicity. No other significant food interactions; however, taking with food may reduce GI upset.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hypertension of the newborn (PPHN) (OR 2.1). Second/third trimester: Late pregnancy exposure may increase risk of preterm birth, low birth weight, and neonatal adaptation syndrome (e.g., respiratory distress, feeding difficulties, irritability).
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Fluvoxamine is excreted into breast milk; M/P ratio ranges from 0.29 to 0.59. Relative infant dose is approximately 1.7% of maternal weight-adjusted dose. Low risk of adverse effects in breastfed infants; monitor for drowsiness, poor feeding, and weight gain. AAP classifies as compatible with breastfeeding.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Plasma levels of fluvoxamine may decrease during pregnancy due to increased volume of distribution and enhanced hepatic metabolism. Dose adjustment may be necessary; consider therapeutic drug monitoring to maintain efficacy. Usually, dose can be increased by 50-100% in third trimester, with gradual reduction postpartum to pre-pregnancy levels.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
Luvox (fluvoxamine) is a selective serotonin reuptake inhibitor (SSRI) approved for obsessive-compulsive disorder (OCD) and social anxiety disorder. It has a short half-life (15-22 hours) and no active metabolites, making it suitable for patients with hepatic impairment. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic agents. Luvox is a potent inhibitor of CYP1A2, affecting metabolism of drugs like clozapine, olanzapine, theophylline, and tizanidine. Titrate slowly; start at 50 mg nightly and increase by 50 mg every 4-7 days to a max of 300 mg daily (divided for doses >100 mg). Discontinuation syndrome is common; taper gradually.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take Luvox exactly as prescribed, usually once daily at bedtime to minimize daytime drowsiness.,It may take several weeks to feel the full effect; do not stop abruptly without consulting your doctor.,Avoid grapefruit juice, which can increase Luvox levels and side effects.,Report any signs of serotonin syndrome (hallucinations, agitation, rapid heart rate, fever, muscle stiffness) immediately.,Do not drive or operate heavy machinery until you know how Luvox affects you, as it can cause drowsiness or dizziness.,Limit alcohol consumption; alcohol can worsen sedation and increase risk of side effects.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
"Tetracycline may inhibit the metabolism of Fluvoxamine via cytochrome P450 enzyme interference, leading to increased Fluvoxamine plasma concentrations. This elevation potentiates serotonergic effects and may precipitate serotonin syndrome, characterized by hyperthermia, autonomic instability, and neuromuscular abnormalities. Concurrent use requires careful monitoring for signs of toxicity such as agitation, confusion, and tachycardia."
"Dexlansoprazole, a proton pump inhibitor (PPI), may inhibit CYP1A2, the primary enzyme responsible for metabolizing fluvoxamine, a selective serotonin reuptake inhibitor (SSRI). This interaction can lead to increased plasma concentrations of fluvoxamine, potentiating its serotonergic effects and risk of dose-dependent adverse events such as nausea, somnolence, and serotonin syndrome. Clinicians should monitor for signs of fluvoxamine toxicity and consider dose adjustment when initiating or discontinuing dexlansoprazole."
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUVOX vs CELEXA, answered by our medical review team.
LUVOX is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUVOX and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUVOX is: Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUVOX and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUVOX is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiac defects (RR ~1.5-2) based on observational studies; also associated with persistent pulmonary hype. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.